Belantamab mafodotin (GSK2857916) is an investigational antibody-drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. BCMA is a pathway proven to be crucial for myeloma cell growth and survival; it is universally detected in myeloma cell lines. It is currently in clinical development by GlaxoSmithKline (GSK) together with Seattle Genetics in patients with relapsed/refractory multiple myeloma and other advanced haematologic malignancies expressing BCMA.
Recruitment updated as of Jan 2021
A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma.
Prospective, multicentre, open label trial, phase II study
Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile
TRIAL PRINCIPAL INVESTIGATOR
Associate Professor Hang Quach
2018 – 2024
Patients with relapsed refractory multiple myeloma who have had 1 to 3 prior lines of treatment